熱門資訊> 正文
IO生物技术第三阶段：Cylembio Plus KEYTRUDA将一线晚期黑色素瘤的中位无进展期延长至19.4个月，尽管统计学意义上的差距很小，但仍显示出具有临床意义的改善
2025-10-20 14:48
- IO Biotech, Inc.(IOBT) 0
- KeyCorp(KEY) 0
- VanEck ETF Trust VanEck Consumer Discretionary TruSector ETF(TRUD) 0
- Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free survival (PFS) primary endpoint for statistical significance
-
- Improvement in PFS favored the combination across virtually all subgroups, notably in patients with PD-L1-negative tumors, BRAFV600-mutated tumors, and elevated LDH, without adding any systemic toxicity compared to pembrolizumab alone
- Final data from the Phase 2 basket trial in lung and head & neck cancers also presented
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
